ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Leukemia
Acute Myeloid Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Berlin, BE, DEU:

A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed ...

Enrolling
Leukemia, Myeloid, Acute
Drug: Azacitidine (AZA)
Drug: Cytarabine

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Berlin, Germany and 30 other locations

Acute myeloid leukemia (AML): continuous oral Venetoclax (VEN) and 7 days of s.c. Azacitidine (AZA) per 28-day cy...

Enrolling
Acute Myeloid Leukemia (AML)
Drug: VEN+AZA-5

Phase 2

University of Leipzig

Berlin, Germany and 9 other locations

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute...

Enrolling
Relapsed or Refractory Acute Myeloid Leukemia
Drug: Tuspetinib
Drug: Venetoclax Oral Tablet

Phase 1, Phase 2

Aptose Biosciences

Berlin, Germany and 33 other locations

This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 i...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: MBG453

Phase 2

Novartis
Novartis

Berlin, Germany and 27 other locations

when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Berlin, Berlin, Germany and 108 other locations

This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. ...

Active, not recruiting
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Acute Myeloid Leukemia (AML)
Drug: azacitidine
Drug: gilteritinib

Phase 3

Astellas
Astellas

Berlin, Germany and 110 other locations

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) ...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

Phase 3

Celgene
Celgene

Berlin, Germany and 222 other locations

Older patients with acute myeloid leukemia (AML) have a small (\< 10%) chance of long-term survival. Despite the ...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: decitabine
Drug: standard combination chemotherapy

Phase 3

European Organisation for Research and Treatment of Cancer (EORTC)

Berlin, Germany and 52 other locations

with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitr...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Azacitidine
Drug: AG-120

Phase 1, Phase 2

Celgene
Celgene

Berlin, Germany and 48 other locations

Activating mutations in the fms like tyrosine kinase 3 (FLT3) gene are observed in approximately 30% of patients with newly diagnosed acute ...

Active, not recruiting
Acute Myeloid Leukemia
Myelodysplastic Syndrome With Excess Blasts-2
Drug: Midostaurin
Drug: Gilteritinib

Phase 3

Stichting Hemato-Oncologie voor Volwassenen Nederland

Berlin, Germany and 193 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems